Transcat (TRNS) Competitors $74.55 -1.88 (-2.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$74.54 -0.01 (-0.01%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRNS vs. TXG, EYPT, ALNT, LAB, AEHR, CTKB, SENS, QSI, QTRX, and MASSShould you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Transcat vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Allient Standard BioTools Aehr Test Systems Cytek Biosciences Senseonics Quantum-Si Quanterix 908 Devices 10x Genomics (NASDAQ:TXG) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends. Which has more volatility and risk, TXG or TRNS? 10x Genomics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Do institutionals & insiders believe in TXG or TRNS? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 2.8% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is TXG or TRNS more profitable? Transcat has a net margin of 5.21% compared to 10x Genomics' net margin of -25.14%. Transcat's return on equity of 6.47% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Transcat 5.21%6.47%5.02% Does the media prefer TXG or TRNS? In the previous week, 10x Genomics had 5 more articles in the media than Transcat. MarketBeat recorded 10 mentions for 10x Genomics and 5 mentions for Transcat. 10x Genomics' average media sentiment score of 0.72 beat Transcat's score of 0.59 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Transcat 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TXG or TRNS? 10x Genomics currently has a consensus target price of $13.23, indicating a potential upside of 1.13%. Transcat has a consensus target price of $112.20, indicating a potential upside of 50.50%. Given Transcat's stronger consensus rating and higher probable upside, analysts clearly believe Transcat is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.42Transcat 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has stronger earnings & valuation, TXG or TRNS? Transcat has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.64-$182.63M-$1.30-10.06Transcat$278.42M2.50$14.52M$1.5647.79 SummaryTranscat beats 10x Genomics on 9 of the 16 factors compared between the two stocks. Get Transcat News Delivered to You Automatically Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRNS vs. The Competition Export to ExcelMetricTranscatINSTRU IndustryComputer SectorNASDAQ ExchangeMarket Cap$712.21M$2.96B$29.20B$9.51BDividend YieldN/A1.01%3.08%4.09%P/E Ratio47.7926.4348.0923.80Price / Sales2.502.831,544.9766.58Price / Cash17.9114.8638.0757.96Price / Book2.423.377.415.55Net Income$14.52M$91.11M$782.10M$259.03M7 Day Performance-11.41%-5.32%-3.65%-4.59%1 Month Performance-16.09%-4.16%-0.11%4.46%1 Year Performance-30.72%11.04%52,642.35%18.03% Transcat Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRNSTranscat3.3122 of 5 stars$74.55-2.5%$112.20+50.5%-32.9%$712.21M$278.42M47.791,245Upcoming EarningsTXG10x Genomics3.7695 of 5 stars$11.54-5.0%$14.13+22.4%-33.5%$1.42B$610.78M-8.881,240News CoverageUpcoming EarningsAnalyst ForecastShort Interest ↑Gap DownEYPTEyepoint Pharmaceuticals1.91 of 5 stars$10.54+1.2%$25.67+143.5%+6.4%$725.27M$56.04M-4.37120News CoverageUpcoming EarningsALNTAllient2.3313 of 5 stars$38.57-3.1%$31.00-19.6%+38.5%$674.11M$529.97M29.072,525News CoveragePositive NewsUpcoming EarningsLABStandard BioTools3.3857 of 5 stars$1.26+2.4%$2.50+98.4%-8.5%$478.57M$174.43M-3.60620News CoveragePositive NewsGap DownAEHRAehr Test Systems1.6485 of 5 stars$16.45+9.2%N/A+1.8%$448.65M$58.97M0.0090CTKBCytek Biosciences2.3493 of 5 stars$3.10-1.0%$5.60+80.6%-43.2%$396.44M$200.45M0.00500Positive NewsUpcoming EarningsSENSSenseonics1.6275 of 5 stars$0.58-0.4%$1.55+168.3%+21.1%$378.01M$23.68M-4.4490QSIQuantum-Si2.5306 of 5 stars$1.72-2.3%$3.48+102.0%+47.6%$315.62M$3.06M-2.53150Upcoming EarningsGap DownQTRXQuanterix2.2462 of 5 stars$5.18-3.5%$13.50+160.6%-58.3%$258.74M$137.42M-3.98460Positive NewsUpcoming EarningsMASS908 Devices2.115 of 5 stars$6.96+3.9%$5.33-23.4%+26.4%$249.59M$59.63M-12.8960Positive NewsUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies TXG Competitors EYPT Competitors ALNT Competitors LAB Competitors AEHR Competitors CTKB Competitors SENS Competitors QSI Competitors QTRX Competitors MASS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRNS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Transcat, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Transcat With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRNS Stock Alerts